IMAPAC Glossary

An equity consideration evaluates whether healthcare access, clinical research or treatment strategies are fair and inclusive across different patient populations.

An equivalence margin definition establishes the acceptable range within which two treatments are considered clinically equivalent in an equivalence study.

Ergonomic workplace design optimises work environments to improve safety, efficiency, comfort and human performance while reducing injury risk.

Ethical Data Sharing Framework establishes principles and governance for responsible sharing of research and clinical data while protecting privacy and confidentiality.

Ethical framework application ensures scientific, clinical and operational decisions are guided by established ethical principles, regulatory expectations and patient welfare.

Europeanisation strategy adapts products, processes or regulatory approaches to meet European market requirements and harmonised standards.

European Pharmacopoeia standards define official quality specifications and analytical methods for medicines and pharmaceutical substances marketed in Europe.

Event-Based Pharmacovigilance systematically identifies and evaluates safety information from spontaneous reports, scientific literature and other real-world sources to detect potential medicine-related risks.

An event-driven trial design continues until a predefined number of clinical events has occurred rather than ending after a fixed study duration.

Evidence Hierarchy Navigation assesses and prioritises scientific evidence according to its methodological quality and relevance to support informed clinical and regulatory decision-making.

Evidence Synthesis Method systematically combines findings from multiple studies to provide comprehensive and reliable conclusions for healthcare decision-making.

Exact Mass Determination accurately measures the molecular mass of a compound using high-resolution mass spectrometry to confirm its identity and composition.

Excipient Function Classification categorises formulation excipients according to their technological roles, such as stabilisers, preservatives, binders or solubilisers.

Excipients are pharmacologically inactive substances added to drug formulations to support stability, manufacturability, delivery and patient acceptability.

Excipient selection criteria define the scientific and technical factors used to choose inactive formulation ingredients that support product quality and performance.

Exclusion criteria are predefined conditions or patient characteristics that prevent participation in a clinical trial to protect safety and data validity.

Excretion Profile Variability assesses differences in drug elimination between individuals caused by physiological, genetic or disease-related factors.

Excretion Route Characterisation determines how a therapeutic product is eliminated from the body through renal, biliary, pulmonary or other excretory pathways.

Executive Safety Summary provides a concise overview of key safety findings, risks and benefit-risk considerations for regulatory or clinical review.

Exercise Capacity Assessment measures physical performance and functional endurance to evaluate disease severity, treatment response or rehabilitation outcomes.

Exogenous Contamination Prevention implements controls to minimise contamination from external environmental, chemical or biological sources during manufacturing and testing.

An exon is a gene sequence retained in mature RNA that may encode part of a protein or perform a functional regulatory role.

An exosome is a small extracellular vesicle that transports proteins, lipids and nucleic acids between cells for communication and potential therapeutic delivery.

Expanded Access Programme provides eligible patients with access to investigational therapies outside clinical trials when no satisfactory approved treatment is available.

Experimental Design Optimisation improves study design by selecting appropriate variables, controls and statistical methods to maximise data quality and experimental efficiency.

Experiment Documentation Standard establishes consistent requirements for recording experimental procedures, observations, results and deviations to ensure traceability and reproducibility.

Expert Elicitation Process systematically gathers and analyses expert knowledge to support scientific decision-making when empirical evidence is limited.

Explicit Inclusion Criteria define the specific characteristics participants must meet to be eligible for enrolment in a clinical study.

Exposure-Efficacy Relationship evaluates how drug exposure influences therapeutic response to support dose selection and treatment optimisation.

An exposure-response relationship describes how the concentration or dose of a drug relates to its therapeutic effects or adverse responses.

An exposure-response relationship describes how changes in drug exposure influence therapeutic efficacy or adverse effects.

Exposure Timing Optimisation determines the most appropriate timing of therapeutic exposure to maximise efficacy while minimising adverse effects.

An expression system combines a biological host with genetic tools to produce recombinant proteins, antibodies or other biomolecules.

Extended Pharmacokinetic Study evaluates the long-term absorption, distribution, metabolism and elimination of a therapeutic product beyond initial pharmacokinetic assessments.

Extended release is a formulation approach that delivers an active ingredient gradually over time to prolong therapeutic action and reduce dosing frequency.

External Reference Standard is a qualified reference material obtained from an external source and used to calibrate or verify analytical methods.

Extractable and Leachable Assessment identifies and evaluates chemical substances that may migrate from manufacturing equipment or packaging into pharmaceutical products.

Extraction is the separation of desired compounds from complex biological or chemical materials using physical, chemical or solvent-based methods.

Extraction Efficiency Optimisation improves the recovery of target compounds from biological or chemical samples while minimising losses and impurities.

Extractive Fractional Composition characterises the chemical composition of fractions obtained during extraction to support product quality and analytical evaluation.

Extraneous Matter Specification defines acceptable limits for foreign particles or contaminants to ensure pharmaceutical product quality and safety.

Extravascular Fluid Accumulation is the abnormal build-up of fluid outside blood vessels that may result in oedema or tissue swelling.

Extreme Adverse Event Classification categorises exceptionally severe or uncommon adverse events to support safety evaluation and regulatory reporting.

Extreme Bioavailability Variability describes unusually large differences in drug absorption between individuals that may influence dosing and clinical outcomes.

Extremely Rare Disease Consideration addresses the unique scientific, clinical and regulatory challenges associated with developing therapies for ultra-rare diseases.

Ex vivo refers to biological processes, experiments or therapies performed on living cells or tissues outside the body.

Eye Drop Formulation Sterility ensures ophthalmic products remain free from viable microorganisms throughout manufacturing, storage and patient use.

Eye Irritation Potential evaluates the likelihood that a substance will cause irritation or damage to ocular tissues following exposure.

Fast-Track Designation is an expedited regulatory programme that facilitates the development and review of medicines addressing serious conditions and unmet medical needs.

The Fc region is the crystallisable portion of an antibody that interacts with immune receptors and complement proteins to mediate effector functions.

FDA 483 Observation Resolution addresses inspection observations through corrective and preventive actions to restore regulatory compliance and manufacturing quality.

Feasibility Assessment Protocol defines the methods used to determine whether a proposed study or project can be successfully conducted with available resources.

A feasibility study design evaluates whether a proposed clinical study or development programme can be successfully conducted using available resources and patient populations.

Fermentation is the controlled cultivation of microorganisms or cells to produce therapeutic proteins, metabolites and other biological products.

Fill-finish is the final manufacturing stage in which sterile drug products are filled into containers, sealed, inspected and prepared for distribution.

Finite Partial Least Squares is a statistical modelling technique used to analyse complex datasets containing highly correlated variables and multiple response outcomes.

A first-in-human trial is the initial clinical study in which an investigational therapy is administered to people to evaluate safety and tolerability.

Flexible dosage form design develops pharmaceutical formulations that accommodate different patient needs while maintaining product quality, stability and therapeutic performance.

Flow cytometry is an analytical technology that rapidly measures physical and biological characteristics of individual cells or particles in suspension.

Flow injection analysis is an automated analytical technique in which liquid samples are injected into a flowing carrier stream for rapid chemical analysis.

A fluorescence polarisation immunoassay measures molecular interactions by detecting changes in fluorescence polarisation during antigen-antibody binding.

Folding intermediate characterisation identifies and analyses transient protein folding states to better understand protein stability, structure and manufacturing behaviour.

Forced degradation deliberately exposes a drug substance or product to stressful conditions to identify degradation pathways and assess stability-indicating methods.

A formulation buffer is a solution that maintains the pH, stability, solubility and biological activity of a pharmaceutical product.

Formulation Excipient Compatibility assesses interactions between active ingredients and excipients to ensure product stability, safety and performance.

Formulation pH optimisation adjusts the acidity or alkalinity of a pharmaceutical formulation to maximise stability, solubility, efficacy and patient compatibility.

Formulation robustness testing evaluates the ability of a pharmaceutical formulation to maintain consistent performance despite expected manufacturing or environmental variations.

Fouling is the unwanted accumulation of biological or chemical material on equipment, membranes or surfaces, reducing process efficiency and performance.

Fractionation separates a complex mixture into distinct components or fractions according to differences in physical or chemical properties.

Free drug concentration is the unbound fraction of a medicine available to distribute into tissues and interact with its biological target.

A freeze-thaw cycle is one complete freezing and thawing event that may affect the stability, structure or biological activity of a product.

Freeze-Thaw Stability Testing evaluates the effect of repeated freezing and thawing on the stability, potency and quality of pharmaceutical products.

Frequency Distribution Analysis evaluates how data values are distributed within a dataset to identify patterns, variability and underlying statistical characteristics.

A functional assay measures the biological activity of a product by evaluating its effect on cells, enzymes, receptors or other biological systems.

Functional impurity assessment evaluates whether impurities influence the biological activity, safety or efficacy of a pharmaceutical product.

Fungal Contamination Prevention implements measures to prevent fungal contamination during pharmaceutical manufacturing, storage and laboratory operations.

A fusion protein is a recombinant molecule combining functional regions from two or more proteins to create enhanced or novel therapeutic properties.

Fusion Protein Engineering designs and modifies recombinant proteins by combining functional domains to enhance therapeutic activity, stability or targeting.

A fusion tag is a short peptide or protein sequence genetically attached to a target protein to support purification, detection, solubility or localisation.

Gadolinium chelate safety assesses the stability, toxicity and clinical risks associated with gadolinium-based contrast agents used in diagnostic imaging.

Gastric acidity modulation alters stomach acid production or pH to improve therapeutic outcomes, drug absorption or gastrointestinal health.

Gastrointestinal motility effects evaluate how therapeutic products influence the movement of the digestive tract, affecting drug absorption and gastrointestinal function.

Gene expression profiling measures messenger RNA levels across multiple genes to identify biological pathways, disease signatures and treatment responses.

Gene knockout is the targeted disruption or deletion of a gene to eliminate its function for research, target validation or cell-line engineering.

Gene panel testing simultaneously analyses a selected group of disease-associated genes to identify clinically relevant genetic variants.

Gene regulation comprises the molecular mechanisms controlling when, where and to what extent genes are expressed within cells.

Gene silencing reduces or prevents the expression of a specific gene without changing its DNA sequence, often using RNA-based mechanisms.

Gene therapy introduces, replaces or modifies genetic material in a patient's cells to treat or prevent disease at its underlying genetic cause.

Gene therapy vector manufacturing produces viral or non-viral delivery systems capable of safely and efficiently transporting therapeutic genetic material into target cells.

Genetic biomarker stratification classifies patients according to genetic biomarkers to support precision medicine and optimise therapeutic selection.

A genetic polymorphism is a common DNA sequence variation within a population that may influence biological traits, drug metabolism or treatment response.

Genome editing precisely modifies DNA sequences within living cells using programmable technologies such as CRISPR-Cas systems.

Genotoxic impurity control identifies, monitors and limits DNA-reactive impurities to minimise mutagenic risk and ensure regulatory compliance.

Genotoxicity is the ability of a chemical or biological agent to damage DNA or chromosomes, potentially causing mutations, cancer or heritable defects.

A genotoxicity threshold defines the exposure level below which a substance is considered unlikely to present a significant risk of genetic damage.

Global regulatory harmonisation aligns pharmaceutical standards across regions to reduce duplication and support consistent quality, safety and efficacy requirements.

Global regulatory harmonisation aligns pharmaceutical regulations and technical requirements across regions to improve product development, approval and international access.

Glycan heterogeneity is the natural variation in carbohydrate structures attached to glycoproteins due to differences in cells and manufacturing conditions.

Glycobiology is the scientific study of carbohydrate structures, biosynthesis and functions, including their effects on therapeutic protein properties.

Glycoengineering deliberately modifies the glycosylation patterns of therapeutic proteins to improve efficacy, half-life, safety or manufacturability.